Trial Profile
A Phase I, Open-label, Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Milategrast (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors EA Pharma
- 05 Sep 2019 Status changed to completed.
- 26 Feb 2018 New trial record